- Home
- OBIO
as 04-18-2025 1:40pm EST
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HOPE |
| Market Cap: | 151.3M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 69.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.49 - $8.87 | Next Earning Date: | 05-12-2025 |
| Revenue: | $2,638,000 | Revenue Growth: | -4.42% |
| Revenue Growth (this year): | 27.37% | Revenue Growth (next year): | 42.68% |
Latest Orchestra BioMed Holdings Inc. News
OBIO Breaking Stock News: Dive into OBIO Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
GlobeNewswire
19 days ago
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
Simply Wall St.
a month ago
Freightos And 2 Other Penny Stocks Worth Watching
MT Newswires
a month ago
BTIG Initiates Orchestra BioMed at Buy With $12 Price Target
GlobeNewswire
2 months ago
Orchestra BioMed to Present at Upcoming Investor Conferences
GlobeNewswire
2 months ago
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
MT Newswires
2 months ago
Orchestra BioMed Says AVIM Therapy Improves Echo Markers of Diastolic Dysfunction
GlobeNewswire
2 months ago
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
Compare OBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OBIO Orchestra BioMed Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.